Latest News

01-12-2015 Shareholder Briefings
25-11-2015 AGM Presentation
25-11-2015 AGM Results
17-11-2015 Corporate Governance Statement
17-11-2015 Proprietary anti-cancer drug candidates
News archive

Subscribe to our newsletter

Receive our latest news and announcements instantly


Phylogica is a leading peptide drug discovery company that utilises proprietary Phylomer peptide libraries and screening methodologies to identify unique peptide drug candidates for its pharmaceutical and biotechnology partners.

Phylomer® libraries contain the world's largest and most structurally diverse array of natural peptides. These peptides, known as Phylomer® peptides, are sourced from evolutionary diverse microbes and they represent a new class of biological therapeutics. Phylomer® peptides display exceptional structural stability, specificity and affinity thereby giving them the potential to address disease targets that are intractable to small molecules and other protein biologics including antibodies. Read more



© 2015 Phylogica    |    ABN 48 098 391 961    |    Privacy Statement
Last updated: 01-12-2015    |    Website by Harmonic New Media and College Hill Life Sciences